[Socium] Socium, an AI drug discovery venture that takes on the challenge of overcoming “unmet medical needs,” launches stock investment crowdfunding today
*View in browser* *Socium Co., Ltd.*
Press release: June 9, 2024
**
Socium, an AI drug discovery venture that takes on the challenge of overcoming “unmet medical needs,” launches equity investment crowdfunding today
June 9, 2024
NEWS RELEASE
Socium Co., Ltd.
Representative Director Katsuhisa Horimoto
* Socium Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Representative Director) Katsuhisa Horimoto (hereinafter referred to as “Socium”) has started accepting investment applications on the stock investment crowdfunding service “FUNDINNO” from 10:00 a.m. today, June 9, 2024 (Sunday). I will. *
[Our project page]
Recruitment started today, June 9, 2024 (Sunday) at 10:00 am. Please refer to the project page below for investment application details. https://fundinno.com/projects/556
[Investor registration form for priority screening]
Registration requires a certain amount of time, so please register using the link below as soon as possible. (If you apply from the URL below, you will be given priority screening.)
https://fundinno.com/users/sign_up?invite_token=qy4nid9a3z
[About implementing crowdfunding]
Through this financing, we will provide bridge financing to expedite the out-licensing of the pipeline in the ALS (amyotrophic lateral sclerosis) field, and at the same time, we will address the social issues of the existence of rare diseases and unmet medical needs. We hope that this will be an opportunity for people to pay attention to us.
Please see the crowdfunding page below for a detailed explanation of the project.
https://fundinno.com/projects/556
[About Socium Co., Ltd.]
Socium Inc. is a drug discovery venture company that discovers first-in-class low-molecular-weight compounds. With our vision of “bringing medicine to those who don’t have it, and medicine to those for whom it doesn’t work,” we are working to overcome the unmet medical needs of patients suffering from diseases. Unique AI drug discovery platform Compound-Eyes(TM), Drug
Using Saver(TM) and Cyber-Drug-Discovery(TM), we are not limited to conventional pharmacological targets, but are searching for novel drug targets based on molecular information such as gene expression and elucidating mechanisms of action. We are trying to find out. We currently have a development portfolio that includes cancer, intractable diseases, and rare diseases. For more information, please visit the Socium homepage (
Please see https://socium.co.jp/ja/).
[Contact information regarding this matter]
Socium Co., Ltd.
2-4-7 Aomi, Koto-ku, Tokyo
National Institute of Advanced Industrial Science and Technology Waterfront City Center
Bio-IT fusion research building 5th, 6th, and 7th floors
https://socium.co.jp/ja/
E-mail: contact@socium.co.jp
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000010.000097494.html
*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=97494&release_id=10
Unsubscribe HTML email
Copyright © PR TIMES Corporation All Rights Reserved.